Samsung venture bringing breast cancer biosimilar to Europe
Samsung Bioepis becomes first to win EU approval for alternative to blockbuster drug
Samsung Bioepis is now approved to sell four biosimilar drugs in Europe.
SEOUL -- Samsung Bioepis will soon debut a biosimilar alternative to a top-selling breast cancer drug in Europe, marking a step forward for the Samsung conglomerate's pharmaceutical operations.
Produced by biological processes, biosimilars have nearly the same effect as existing pharmaceuticals but unlike generics, are not exact copies.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30